Guneet Janda
About
Research
Publications
2025
Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma
Nishimura Y, Han Y, Toumeh N, Janda G, Fujiwara Y, Durani U, Nowakowski G, Paludo J, Ansell S, Abeykoon J. Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma. Blood Neoplasia 2025, 2: 100134. PMID: 40809195, PMCID: PMC12346057, DOI: 10.1016/j.bneo.2025.100134.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalImmune checkpoint inhibitors rechallengeOverall response rateHodgkin lymphomaAdverse eventsICI rechallengeComplete responseResponse rateMedian progression-free survivalImmune-related adverse eventsRelapsed/Refractory Hodgkin LymphomaPooled response rateConfidence intervalsClassical HLICI therapyR/R HLCheckpoint inhibitorsAny-gradeSystematic literature searchCR ratePatient selectionSafety profileRechallengePreferred Reporting ItemsUtilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders.
Janda G, Goetz M, Haddad T, Peethambaram P, Leon-Ferre R, Calkins H, Scott N, Rodriguez A, Liu M, Giridhar K. Utilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders. Journal Of Clinical Oncology 2025, 43: e13042-e13042. DOI: 10.1200/jco.2025.43.16_suppl.e13042.Peer-Reviewed Original ResearchMetastatic breast cancerSystemic therapyCtDNA testingContinuous endocrine therapyRadiographic remissionRestaging scansEndocrine therapyExceptional respondersER+/HER2- metastatic breast cancerCohort of ptsDiscontinued systemic therapySystemic therapy optionsTreatment de-escalationBreast cancer characteristicsMedian Follow-UpDe-escalate treatmentTreating medical oncologistMetastatic breast cancer diagnosisIRB-approved protocolIncreased imaging frequencyConventional treatment paradigmsProgression of diseaseCtDNA-positiveHER2+Median durationResearch Derived From Medicare’s Coverage With Evidence Development Program
Janda G, Moneer O, Mooghali M, Ramachandran R, Wallach J, Dhruva S, Ross J. Research Derived From Medicare’s Coverage With Evidence Development Program. JAMA Network Open 2025, 8: e255077. PMID: 40232723, PMCID: PMC12000966, DOI: 10.1001/jamanetworkopen.2025.5077.Peer-Reviewed Original ResearchCharacterization of studies considered and required under Medicare’s coverage with evidence development program
Mooghali M, Moneer O, Janda G, Ross J, Dhruva S, Ramachandran R. Characterization of studies considered and required under Medicare’s coverage with evidence development program. Clinical Trials 2025, 22: 619-625. PMID: 39921418, DOI: 10.1177/17407745251313979.Peer-Reviewed Original ResearchCenters for MedicareMedicare beneficiariesIdentified original research articlesMedicare coverageClinical trial studyEvidence developmentTrial studyQuality of evidenceCoverage decisionsPrimary endpointClinical outcome measuresEvidence of benefitRandomized study designClinical studiesOriginal research articlesDecision MemoMedicaid ServicesOutcome measuresNational Coverage DeterminationMedicareMulti-arm designStudy designDissemination of studiesGoogle ScholarUS patientsAlterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis
Gupta V, Janda G, Pump H, Lele N, Cruz I, Cohen I, Ruff W, Hafler D, Sung J, Longbrake E. Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2025, 12: e200355. PMID: 39819054, PMCID: PMC11741292, DOI: 10.1212/nxi.0000000000200355.Peer-Reviewed Original ResearchConceptsAmplicon sequence variantsIgA-coatedGut microbiomeBacterial fractionRRNA gene amplicon sequencingLong-read sequencingGut microbial symbiontsGene amplicon sequencingMultiple sclerosisStool samplesProportion of bacteriaB cellsHost-microbial interfaceAnti-CD20 monoclonal antibody treatmentDiagnosing MSMicrobial symbiontsIgA-secreting B cellsTaxonomic resolutionSequence variantsAmplicon sequencingB-cell depletionFecal microbiotaMonths of treatmentMonoclonal antibody treatmentDevelopment of autoimmunityAssessing Medicare’s Coverage With Evidence Development Program
Mooghali M, Moneer O, Janda G, Dhruva S, Ross J, Ramachandran R. Assessing Medicare’s Coverage With Evidence Development Program. Health Affairs 2025, 44: 32-39. PMID: 39761464, DOI: 10.1377/hlthaff.2024.00814.Peer-Reviewed Original Research
2024
Feasibility of using real-world data to emulate substance use disorder clinical trials: a cross-sectional study
Janda G, Jeffery M, Ramachandran R, Ross J, Wallach J. Feasibility of using real-world data to emulate substance use disorder clinical trials: a cross-sectional study. BMC Medical Research Methodology 2024, 24: 187. PMID: 39198727, PMCID: PMC11351457, DOI: 10.1186/s12874-024-02307-1.Peer-Reviewed Original ResearchConceptsElectronic health record dataElectronic health recordsSubstance use disordersCross-sectional studyAdministrative claimsEligibility criteriaTrials evaluating treatmentPublic health systemClinical trialsIntroductionReal-world evidenceSafety of medical productsHealth recordsHealth systemReal-world dataTrial emulationPrimary end pointInsurance claimsPhase 2Placebo comparatorActive comparatorInterventionEligibilityEnd pointsTrialsHPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates
Mooghali M, Moneer O, Janda G, Dhruva S, Ross J, Ramachandran R. HPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates. Value In Health 2024, 27: s214. DOI: 10.1016/j.jval.2024.03.1178.Peer-Reviewed Original ResearchHypothetical Assessments of Trial Emulations—Reply
Janda G, Wallach J, Ross J. Hypothetical Assessments of Trial Emulations—Reply. JAMA Internal Medicine 2024, 184: 446-447. PMID: 38345787, DOI: 10.1001/jamainternmed.2023.7948.Peer-Reviewed Original Research
2022
Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles
Janda G, Khetpal V, Shi X, Ross J, Wallach J. Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles. JAMA Network Open 2022, 5: e2245847. PMID: 36484989, PMCID: PMC9856222, DOI: 10.1001/jamanetworkopen.2022.45847.Peer-Reviewed Original ResearchConceptsPrimary end pointPrimary end point resultsPeer-reviewed journalsClinical studiesEnd pointClinical trialsObservational studyStudy characteristicsEnd point resultsClinical study resultsMost clinical studiesCross-sectional studyHealth-related outcomesSample sizeMAIN OUTCOMEPeer-reviewed publicationsMedRxivEffect estimatesStudy interpretationDiscordant pairsCOVID-19Trials